Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Active not recruiting 2Terminated 1

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3Gynecologic 2

Conditions

Prostatic Neoplasms 29Multiple Myeloma 26Breast Neoplasms 24Carcinoma, Non-Small-Cell Lung 22Leukemia, Myeloid, Acute 21Lymphoma 20Melanoma 16Lymphoma, Non-Hodgkin 14Colorectal Neoplasms 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Ovarian Neoplasms 13Wilms Tumor 11Myelodysplastic Syndromes 10Lung Neoplasms 10Hodgkin Disease 10Squamous Cell Carcinoma of Head and Neck 9Sarcoma 9Neoplasm Metastasis 9Fallopian Tube Neoplasms 9Carcinoma, Renal Cell 9Burkitt Lymphoma 9Rhabdomyosarcoma 8Rhabdoid Tumor 8Neoplasms 8Leukemia 8Hepatoblastoma 8Glioma 8Colonic Neoplasms 8Sarcoma, Ewing 7Osteosarcoma 7

Interventions

Specimen Handling 2Biopsy 2olaparib 1durvalumab 1cediranib 1capivasertib 1cabozantinib 1Nivolumab 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Fluid Therapy 1Disulfides 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Carcinosarcoma × 30 days × Clear all
NCT05949632 2026-06-04

A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors

Incyte Corporation

Phase 1/2 Terminated
5 enrolled 13 charts
GynecologicSarcoma

Adenocarcinoma, Mucinous, Carcinosarcoma, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Uterine Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Cystadenocarcinoma, Serous

NCT03367741 2026-06-02

Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
82 enrolled 11 charts
GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

NCT03660826 2026-06-02

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

National Cancer Institute (NCI)

Phase 2 Active not recruiting
288 enrolled 21 charts
Sarcoma

Carcinosarcoma, Carcinoma, Endometrioid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡